Journal
CANCER RESEARCH
Volume 71, Issue 3, Pages 661-665Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-10-1259
Keywords
-
Categories
Funding
- Ligue Nationale contre le Cancer
- Association pour la Recherche sur le Cancer (ARC)
- Fondation pour la Recherche Medicale en France (FRM)
- Institut National du Cancer (INCa)
- INFLA-CARE [Health-2007-2.4.1-10]
- Novartis
- Fondation de France contre la Leucemie
- INSERM
Ask authors/readers for more resources
Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and cancer patients that CTX markedly promotes the differentiation of CD4(+) T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells. Because Th17 are potent inducers of tissue inflammation and autoimmunity, these results suggest impact on the clinical management of various types of malignancies treated with alkylating agents and a potential need to optimize CTX-based immunotherapy in patients. Cancer Res; 71(3); 661-5. (C)2011 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available